Form D · Biotechnology
Dimension Inx Corp.
Chicago, IL · CIK 0001832381
Offering snapshot reported Feb 3, 2023 · SEC filing
- Reported sold
- $12M Offering amount: $15M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 23, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 3, 2023 | Initial | $11,999,993 | No comparison | 17 | SEC filing |
| Nov 29, 2021 | Initial | $2,286,341 | No comparison | 18 | SEC filing |
| Nov 18, 2020 | Initial | $3,385,000 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-472546
Source: Form D, filed Feb 3, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rima Chakrabarti | Director |
| Caralynn Collens | Director, Executive |
| Adam Jakus | Director, Executive |
| Ramille Shah | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3440 South Dearborn Street Suite 142 S
Chicago, IL, 60616
Chicago, IL, 60616